{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sublingual+buprenorphine&page=4",
    "query": {
      "intervention": "sublingual buprenorphine",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 109,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sublingual+buprenorphine&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sublingual+buprenorphine&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T23:22:45.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01157169",
      "title": "Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-08",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157169"
    },
    {
      "nct_id": "NCT03911466",
      "title": "Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Opioid-Related Disorders",
        "Drug Addiction",
        "Pregnancy Related",
        "Substance Abuse",
        "Drug Abuse",
        "Neonatal Abstinence Syndrome",
        "Neonatal Opioid Withdrawal Syndrome",
        "Drug Abuse in Pregnancy"
      ],
      "interventions": [
        {
          "name": "Buprenorphine Injection",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine Sublingual Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "T. John Winhusen, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "41 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 41 Years · Female only"
      },
      "enrollment_count": 97,
      "start_date": "2020-07-21",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 12,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911466"
    },
    {
      "nct_id": "NCT02357901",
      "title": "Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Dependence",
        "Opioid Related Disorders"
      ],
      "interventions": [
        {
          "name": "SUBOXONE",
          "type": "DRUG"
        },
        {
          "name": "RBP-6000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 665,
      "start_date": "2015-01-28",
      "completion_date": "2016-04-29",
      "has_results": true,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 38,
      "location_summary": "Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 33 more",
      "locations": [
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Hamilton",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357901"
    },
    {
      "nct_id": "NCT00733720",
      "title": "Buprenorphine Naltrexone-P1 A-Cocaine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine-related Disorders"
      ],
      "interventions": [
        {
          "name": "Suboxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-08",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733720"
    },
    {
      "nct_id": "NCT04447287",
      "title": "A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "ASP8062",
          "type": "DRUG"
        },
        {
          "name": "Placebo ASP8062",
          "type": "DRUG"
        },
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 23,
      "start_date": "2020-06-29",
      "completion_date": "2020-11-25",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04447287"
    },
    {
      "nct_id": "NCT03852628",
      "title": "Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder",
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "2mg Buprenex and 380mg Vivitrol",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SL pill qd, IM injection q4weeks)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacotherapies for Alcohol and Substance Use Disorders Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 69,
      "start_date": "2019-05-20",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 2,
      "location_summary": "Tuscaloosa, Alabama • West Haven, Connecticut",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852628"
    },
    {
      "nct_id": "NCT05644587",
      "title": "Novel Induction to Buprenorphine/Naloxone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Use",
        "Opioid Abuse",
        "Opioid Misuse",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bicycle Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-02-06",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644587"
    },
    {
      "nct_id": "NCT04948307",
      "title": "OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "OXD01 digital therapy",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Orexo AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 437,
      "start_date": "2021-06-30",
      "completion_date": "2023-05-10",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04948307"
    },
    {
      "nct_id": "NCT05944952",
      "title": "Low-dose Versus a High-dose Sublingual Buprenorphine Induction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Friends Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-06-20",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "Dundalk, Maryland",
      "locations": [
        {
          "city": "Dundalk",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05944952"
    },
    {
      "nct_id": "NCT02477267",
      "title": "Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opiate Dependence"
      ],
      "interventions": [
        {
          "name": "SL spray",
          "type": "DRUG"
        },
        {
          "name": "SL film",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2015-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-09-03",
      "last_synced_at": "2026-10-10T23:22:45.305Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477267"
    }
  ]
}